IP Verse

Crystalline Forms Of A Prolyl Hydroxylase Inhibitor - EP2872488

The patent EP2872488 was granted to Fibrogen on Aug 22, 2018. The application was originally filed on Jul 15, 2013 under application number EP13740185A. The patent is currently recorded with a legal status of "Revoked".

EP2872488

FIBROGEN
Application Number
EP13740185A
Filing Date
Jul 15, 2013
Status
Revoked
Apr 12, 2024
Grant Date
Aug 22, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZMay 22, 2019TER MEER STEINMEISTER & PARTNERADMISSIBLE
TEVA PHARMACEUTICALSMay 21, 2019D YOUNGADMISSIBLE
ZENTIVAMay 20, 2019KRAUS & LEDERERADMISSIBLE
ZENTIVAMay 20, 2019KRAUS & LEDERER PARTGMBBADMISSIBLE

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2006276477
DESCRIPTIONUS2007004627
DESCRIPTIONUS2007259960
DESCRIPTIONUS4558006
DESCRIPTIONUS4667016
DESCRIPTIONUS7323475
DESCRIPTIONWO2005118836
INTERNATIONAL-SEARCH-REPORTUS2004254215
INTERNATIONAL-SEARCH-REPORTWO2013013609
OPPOSITIONUS2004254215
OPPOSITIONWO2004108681
OPPOSITIONWO2012097331
OPPOSITIONWO2013013609
OTHERUS2004254215

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BRUICK; MCKNIGHT, SCIENCE, (2001), vol. 294, pages 1337 - 1340-
DESCRIPTION- EPSTEIN ET AL., CELL, (2001), vol. 107, pages 43 - 54-
DESCRIPTION- KIVIRIKKO; MYLLYLA, METHODS ENZYMOL., (1982), vol. 82, pages 245 - 304-
DESCRIPTION- TAYLOR, GENE, (2001), vol. 275, pages 125 - 132-
OPPOSITION- J.K. GUILLORY, "Generation of polymorphs, hydrates, solvates, and amorphous solids", Polymorphism in Pharmaceutical Solids, (19990000), pages 183 - 226, XP002350313-
OPPOSITION- M. BAVIN, "Polymorphism in process development", Chemistry & Industry, (19980000), vol. 21, pages 527 - 529, XP001180136-
OPPOSITION- Alfons Grunenberg, "Polymorphie und thermische analyse pharmazeutischer wirkstoffe", Pharmazie in unserer Zeit, (19970000), vol. 26, no. 5, pages 224 - 231, XP055745450
OPPOSITION- M. R. CAIRA, "Crystalline Polymorphism of Organic Compounds", Topics in Current Chemistry, (19980000), vol. 198, pages 164 - 208, XP008166276
OPPOSITION- W. I. CROSS et al., "A Whole Output Strategy for Polymorph Screening: Combining Crystal Structure Prediction, Graph Set Analysis, and Targeted Crystallization Experiments in the Case of Diflunisal", Crystal Growth & Design, (20020000), vol. 3, no. 2, pages 151 - 158, XP055518274
OPPOSITION- S. BYRN et al., "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", Pharmaceutical Research, (19950000), vol. 12, no. 7, pages 945 - 954, XP055531015
OPPOSITION- R. HILFIKER et al., "Polymorphism - integrated approach from high-throughput screening to crystallization optimization", Journal of Thermal Analysis and Calorimetry, (20030000), vol. 73, no. 2, pages 429 - 440, XP002314915

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents